
Koji Takagi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7282615/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Temporal trends in mortality and readmission after acute heart failure: a systematic review and metaâ€regression in the past four decades. European Journal of Heart Failure, 2021, 23, 420-431.	7.1	67
2	Clinical phenotypes of acute heart failure based on signs and symptoms of perfusion and congestion at emergency department presentation and their relationship with patient management and outcomes. European Journal of Heart Failure, 2019, 21, 1353-1365.	7.1	56
3	Circulating dipeptidyl peptidase 3 and alteration in haemodynamics in cardiogenic shock: results from the OptimaCC trial. European Journal of Heart Failure, 2020, 22, 279-286.	7.1	53
4	Safety, Tolerability and efficacy of Rapid Optimization, helped by NTâ€proBNP and GDFâ€15, of Heart Failure therapies (STRONGâ€HF): rationale and design for a multicentre, randomized, parallelâ€group study. European Journal of Heart Failure, 2019, 21, 1459-1467.	7.1	34
5	CORT-AHF Study. JACC: Heart Failure, 2019, 7, 834-845.	4.1	12
6	Work-style reform of emergency physicians: the Japanese experience. European Journal of Emergency Medicine, 2019, 26, 398-399.	1.1	12
7	Megaâ€trials in heart failure: effects of dilution in examination of new therapies. European Journal of Heart Failure, 2020, 22, 1698-1707.	7.1	11
8	Clinical significance of arterial stiffness as a factor for hospitalization of heart failure with preserved left ventricular ejection fraction: a retrospective matched case-control study. Journal of Cardiology, 2020, 76, 171-176.	1.9	10
9	Ethnic differences in acute heart failure outcomes in Ontario. International Journal of Cardiology, 2019, 291, 177-182.	1.7	9
10	Management of Acute Heart Failure during an Early Phase. International Journal of Heart Failure, 2020, 2, 91.	2.7	9
11	Time-pattern of adverse outcomes after an infection-triggered acute heart failure decompensation and the influence of early antibiotic administration and hospitalisation: results of the PAPRICA-3 study. Clinical Research in Cardiology, 2020, 109, 34-45.	3.3	8
12	Adrecizumab: an investigational agent for the biomarker-guided treatment of sepsis. Expert Opinion on Investigational Drugs, 2021, 30, 95-102.	4.1	8
13	Analysis of standards of quality for outcomes in acute heart failure patients directly discharged home from emergency departments and their relationship with the emergency department direct discharge rate. Journal of Cardiology, 2021, 77, 245-253.	1.9	8
14	Amended <scp>STRONGâ€HF</scp> study design. European Journal of Heart Failure, 2021, 23, 1981-1982.	7.1	8
15	Influence of the length of hospitalisation in post-discharge outcomes in patients with acute heart failure: Results of the LOHRCA study. European Journal of Internal Medicine, 2019, 70, 24-32.	2.2	7
16	Effects of tolvaptan on urine output in hospitalized heart failure patients with hypoalbuminemia or proteinuria. Heart and Vessels, 2018, 33, 413-420.	1.2	6
17	Effect of systemic corticosteroid therapy for acute heart failure patients with elevated Câ€reactive protein. ESC Heart Failure, 2022, 9, 2225-2232.	3.1	6
18	Acute heart failure treatment: a light at the end of the tunnel?. European Journal of Heart Failure, 2021, 23, 698-702.	7.1	5

Κοјι Τάκαςι

#	Article	IF	CITATIONS
19	Early intravenous nitroglycerin use in prehospital setting and in the emergency department to treat patients with acute heart failure: Insights from the EAHFE Spanish registry. International Journal of Cardiology, 2021, 344, 127-134.	1.7	5
20	Early echocardiography by treating physicians and outcome in the critically ill: An ancillary study from the prospective multicenter trial FROG-ICU. Journal of Critical Care, 2022, 69, 154013.	2.2	4
21	One-year outcome of patients admitted after cardiac arrest compared to other causes of ICU admission. An ancillary analysis of the observational prospective and multicentric FROG-ICU study. Resuscitation, 2020, 146, 237-246.	3.0	3
22	Differences in pharmacological property between combined therapy of the vasopressin V2-receptor antagonist tolvaptan plus furosemide and monotherapy of furosemide in patients with hospitalized heart failure. Journal of Cardiology, 2020, 76, 499-505.	1.9	3
23	Clinical usefulness of gated technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography with phase analysis for the management of patients with isolated ventricular noncompaction. Journal of Cardiology Cases, 2015, 11, 101-104.	0.5	2
24	Safety of diuretic administration during the early management of dyspnea patients who are not finally diagnosed with acute heart failure. European Journal of Emergency Medicine, 2020, 27, 422-428.	1.1	2
25	Elevated Plasma Bioactive Adrenomedullin and Mortality in Cardiogenic Shock: Results from the OptimaCC Trial. Journal of Clinical Medicine, 2021, 10, 4512.	2.4	2
26	Left ventricular assist devices: let's move toward better quality of extended life, away from hospital. European Heart Journal, 2018, 39, 3461-3463.	2.2	1
27	Medical Therapy of Heart Failure with Reduced Ejection Fraction—A Call for Comparative Research. Journal of Clinical Medicine, 2021, 10, 1803.	2.4	1
28	Reply. JACC: Heart Failure, 2020, 8, 154-155.	4.1	0